BioNet is pleased to announce its participation in the 6th annual International Neonatology and Maternal Immunization Symposium (INMIS 2024), taking place in San Jose, Costa Rica, from March 12th to 14th. This premier global event focuses on neonatology and maternal immunization. BioNet and their collaborators will present seminal data from its phase II/III studies in three oral presentations.
Hong Thai Pham, CEO of BioNet, emphasized the significance of sharing these findings with an international assembly of scientists, healthcare professionals, vaccine manufacturers, and global public health policy leaders. The discussions will revolve around the advancements in maternal and neonatal health through maternal immunization.
A highlight of the symposium will be the oral presentation by our collaborator PATH, a renowned global health organization focused on improving the outcome of women and children. Scheduled for the opening day (March 12th, 10:30-11:30 AM, Session 1), PATH will unveil first-time clinical trial results for infants up to 13 months old following immunization in pregnancy with BioNet’s licensed recombinant pertussis vaccine, Boostagen®, and lower-dose TdaP vaccine candidates.
Moreover, attendees are invited to explore E-posters 163 and 166 on Monitor 2 during the event. These posters will detail additional study results on recombinant pertussis vaccination in pregnancy, including our pioneering monovalent pertussis-only vaccine, Pertagen®. Oral presentations of these posters are scheduled for March 13th, 4:00-5:30 PM.
BioNet’s Vice President of Business Operations North America, Bill Cadwallader, and Director of Science Communications, Anita van den Biggelaar, will be present to engage with the INMIS community. They are keen to discuss collaborative opportunities to combat pertussis disease through maternal immunization with novel pertussis vaccines.
Learn more about INMIS: https://www.inmis.org
